CA2194370A1 - Attenuation of wound healing processes - Google Patents

Attenuation of wound healing processes

Info

Publication number
CA2194370A1
CA2194370A1 CA002194370A CA2194370A CA2194370A1 CA 2194370 A1 CA2194370 A1 CA 2194370A1 CA 002194370 A CA002194370 A CA 002194370A CA 2194370 A CA2194370 A CA 2194370A CA 2194370 A1 CA2194370 A1 CA 2194370A1
Authority
CA
Canada
Prior art keywords
cell
heparinases
extracellular matrix
growth factors
heparan sulfate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002194370A
Other languages
French (fr)
Other versions
CA2194370C (en
Inventor
Israel Vlodavsky
D. Clark Bennett
Pamela Danagher
Richard Broughton
Joseph Zimmermann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biomarin Pharmaceutical Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2194370A1 publication Critical patent/CA2194370A1/en
Application granted granted Critical
Publication of CA2194370C publication Critical patent/CA2194370C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/51—Lyases (4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/825—Bacteria

Abstract

Glycosaminoglycans, including heparinases 1, 2 and 3 as well as chondroitinases AC and B from the Gram negative bacteria Flavobacterium heparinum, can be used either separately or in combination to manipulate cell proliferation. In one embodiment, heparinases are administered to degrade heparan sulfate components of the extracellular matrix, thereby allowing the heparin binding growth factors which are stored in the extracellular matrix to migrate to adjacent cells. The mobility of chemoattractant agents, growth factors and cells also can be increased by treating tissues with glycosaminoglycan degrading enzymes, both chondroitinases and heparinases. The enzymatic removal of chondroitin sulfates from cell surfaces effectively increases the availability of growth factor receptors on the cell's surface.
Selectively removing heparan sulfate from cell surfaces while leaving the extracellular matrix intact, conversely, inhibits cell proliferation by down regulating the cell's response to growth factors. This is achieved by targeting heparin or heparan sulfate degrading activites to the cell surface.
Targeting the heparin degrading activity can be achieved by genetically engineering a ligand binding functionality into the heparinase proteins, or by physically controlling the localized enzyme concentration through the method of administration.
CA002194370A 1994-07-08 1995-07-07 Attenuation of wound healing processes Expired - Fee Related CA2194370C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/273,109 US5997863A (en) 1994-07-08 1994-07-08 Attenuation of wound healing processes
US273,109 1994-07-08
PCT/US1995/008608 WO1996001648A1 (en) 1994-07-08 1995-07-07 Attenuation of wound healing processes

Publications (2)

Publication Number Publication Date
CA2194370A1 true CA2194370A1 (en) 1996-01-25
CA2194370C CA2194370C (en) 2001-02-27

Family

ID=23042598

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002194370A Expired - Fee Related CA2194370C (en) 1994-07-08 1995-07-07 Attenuation of wound healing processes

Country Status (9)

Country Link
US (1) US5997863A (en)
EP (1) EP0769961B1 (en)
JP (1) JP4152433B2 (en)
AT (1) ATE344051T1 (en)
AU (1) AU707007B2 (en)
CA (1) CA2194370C (en)
DE (1) DE69535282T2 (en)
ES (1) ES2279514T3 (en)
WO (1) WO1996001648A1 (en)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1552846A3 (en) * 1995-09-29 2008-05-07 BioMarin Pharmaceutical Inc Use of heparinases to decrease inflammatory responses
WO1997016556A1 (en) 1995-10-30 1997-05-09 Massachusetts Institute Of Technology Rationally designed polysaccharide lyases derived from heparinase i
GB2317182B (en) * 1996-09-11 2000-11-01 Johnson & Johnson Medical Sulfated polysaccharides and uses thereof in medical treatment
US20010006630A1 (en) * 1997-09-02 2001-07-05 Oron Yacoby-Zeevi Introducing a biological material into a patient
US6699672B1 (en) 1997-09-02 2004-03-02 Insight Biopharmaceuticals Ltd. Heparanase specific molecular probes and their use research and medical applications
US20020088019A1 (en) * 1997-09-02 2002-07-04 Oron Yacoby-Zeevi Methods of and pharmaceutical compositions for improving implantation of embryos
US20040213789A1 (en) * 1997-09-02 2004-10-28 Oron Yacoby-Zeevi Heparanase activity neutralizing anti-heparanase monoclonal antibody and other anti-heparanase antibodies
US20030161823A1 (en) * 1998-08-31 2003-08-28 Neta Ilan Therapeutic and cosmetic uses of heparanases
US6177545B1 (en) * 1997-09-02 2001-01-23 Insight Strategy & Marketing Ltd. Heparanase specific molecular probes and their use in research and medical applications
WO1999046368A2 (en) * 1998-03-13 1999-09-16 Biomarin Pharmaceuticals Carbohydrate-modifying enzymes for burn and wound debridement and methods for treatment
US7056504B1 (en) 1998-08-27 2006-06-06 Massachusetts Institute Of Technology Rationally designed heparinases derived from heparinase I and II
JP2003527822A (en) 1998-08-27 2003-09-24 マサチューセッツ インスティテュート オブ テクノロジー Rationally designed heparinases from heparinases I and II
US20030217375A1 (en) * 1998-08-31 2003-11-20 Eyal Zcharia Transgenic animals expressing heparanase and uses thereof
AU2878600A (en) * 1999-03-01 2000-09-21 Hadasit Medical Research Services & Development Company Ltd Polynucleotide encoding a polypeptide having heparanase activity and expression of same in genetically modified cells
CA2370539C (en) 1999-04-23 2009-01-06 Massachusetts Institute Of Technology System and method for notating polymers
US6979563B1 (en) 1999-11-17 2005-12-27 Biomarin Enzymes, Inc. Attenuation of tumor growth, metastasis and angiogenesis
ATE413886T1 (en) * 1999-11-17 2008-11-15 Biomarin Pharm Inc REDUCING ANGIOGENESIS USING CHONDROITIN SULPHATE DEGRADING ENZYMES
WO2001038399A1 (en) * 1999-11-24 2001-05-31 Seikagaku Corporation Method of treating surface tissue diseases
JP2003525946A (en) * 2000-03-08 2003-09-02 マサチューセッツ インスティテュート オブ テクノロジー Heparinase III and uses thereof
CA2422059C (en) 2000-09-12 2012-05-15 Massachusetts Institute Of Technology Methods and products related to low molecular weight heparin
CA2423469A1 (en) 2000-10-18 2002-04-25 Massachusetts Institute Of Technology Methods and products related to pulmonary delivery of polysaccharides
US7262174B2 (en) * 2001-05-09 2007-08-28 Geron Corporation Treatment for wounds
IL160188A0 (en) * 2001-08-13 2004-07-25 Univ Florida Materials and methods to promote repair of nerve tissue
US6671189B2 (en) * 2001-11-09 2003-12-30 Minebea Co., Ltd. Power converter having primary and secondary side switches
GB0205022D0 (en) 2002-03-04 2002-04-17 Univ Cambridge Tech Materials and methods for the treatment of cns damage
US6974592B2 (en) * 2002-04-11 2005-12-13 Ocean Nutrition Canada Limited Encapsulated agglomeration of microcapsules and method for the preparation thereof
US8183350B2 (en) 2002-05-04 2012-05-22 Acorda Therapeutics, Inc. Compositions and methods for promoting neuronal outgrowth
ATE481478T1 (en) * 2002-06-03 2010-10-15 Massachusetts Inst Technology RATIONALLY DESIGNED LYASES DERIVED FROM CHONDROITINASE B
ATE508197T1 (en) * 2002-08-15 2011-05-15 Acorda Therapeutics Inc CHIMERIC PROTEIN
WO2004041251A1 (en) * 2002-11-04 2004-05-21 Ocean Nutrition Canada Limited Microcapsules having multiple shells and method for the preparation thereof
EP2353606B1 (en) * 2003-05-16 2013-04-17 Acorda Therapeutics, Inc. Compositions and methods for the treatment of CNS injuries
CA2525784C (en) 2003-05-16 2019-04-09 Acorda Therapeutics, Inc. Proteoglycan degrading mutants for treatment of cns
US7959914B2 (en) 2003-05-16 2011-06-14 Acorda Therapeutics, Inc. Methods of reducing extravasation of inflammatory cells
US20060269552A1 (en) * 2003-06-09 2006-11-30 Oron Yacoby-Zeevi Heparanase activity neutralizing anti-heparanase monclonal antibody and other anti-heparanase antibodies
EP1737476A4 (en) * 2004-01-30 2009-07-22 Univ Emory Materials and method for promotion of nerve regeneration
US7507570B2 (en) * 2004-03-10 2009-03-24 Massachusetts Institute Of Technology Recombinant chondroitinase ABC I and uses thereof
CA2566731C (en) * 2004-05-18 2012-07-24 Acorda Therapeutics, Inc. Methods of purifying chondroitinase and stable formulations thereof
US8034450B2 (en) * 2005-01-21 2011-10-11 Ocean Nutrition Canada Limited Microcapsules and emulsions containing low bloom gelatin and methods of making and using thereof
US9968120B2 (en) * 2006-05-17 2018-05-15 Dsm Nutritional Products Ag Homogenized formulations containing microcapsules and methods of making and using thereof
US7485295B2 (en) 2005-09-26 2009-02-03 Acorda Therapeutics, Inc. Compositions and methods of using chondroitinase ABCI mutants
WO2007049361A1 (en) * 2005-10-27 2007-05-03 Stelic Corp. Liver fibrosis inhibitor
US7691613B2 (en) * 2006-11-03 2010-04-06 Momenta Pharmaceuticals, Inc. Glycosaminoglycan lyase IV and uses thereof
US7767420B2 (en) * 2005-11-03 2010-08-03 Momenta Pharmaceuticals, Inc. Heparan sulfate glycosaminoglycan lyase and uses thereof
US7691612B2 (en) * 2005-11-03 2010-04-06 Momenta Pharmaceuticals, Inc. Heparan sulfate glycosaminoglycan lyase and uses thereof
EP2007224A2 (en) * 2006-04-07 2008-12-31 Ocean Nutrition Canada Limited Emulsions and microcapsules with substances having low interfacial tension, methods of making and using thereof
KR20090046773A (en) * 2006-06-05 2009-05-11 오션 뉴트리션 캐나다 리미티드 Microcapsules with improved shells
US7722864B2 (en) 2006-10-10 2010-05-25 Acorda Therapeutics, Inc. Compositions and methods of using chondroitinase ABCI mutants
CA2675123C (en) 2007-01-10 2017-04-11 Ocean Nutrition Canada Limited Vegetarian microcapsules
US20090286289A1 (en) * 2008-03-10 2009-11-19 Pang Danny Z Production of Hyaluronate Unsaturated Disaccharides and its Application
US9144601B2 (en) * 2011-09-15 2015-09-29 Seikagaku Corporation Skeletal muscle regeneration promoter
US9238090B1 (en) 2014-12-24 2016-01-19 Fettech, Llc Tissue-based compositions
CN109182321A (en) * 2018-09-14 2019-01-11 深圳市长征生物科技有限公司 The high efficiency preparation method of flavobacterium heparinum heparinase I

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4760131A (en) * 1986-04-23 1988-07-26 Collagen Corporation Wound-healing composition
US5169772A (en) * 1988-06-06 1992-12-08 Massachusetts Institute Of Technology Large scale method for purification of high purity heparinase from flavobacterium heparinum
JPH04503734A (en) * 1988-12-01 1992-07-02 ボック、エドワード Improved equipment for conveying and processing in a pulsating, floating state
US5116615A (en) * 1989-01-27 1992-05-26 Immunolytics, Inc. Method for treating benign prostatic hypertrophy
CA2065744A1 (en) * 1989-08-23 1991-02-24 Zvi Fuks Wound healing preparations containing heparanase
US5242810A (en) * 1990-12-07 1993-09-07 Biogen, Inc. Bifunctional inhibitors of thrombin and platelet activation
US5262325A (en) * 1991-04-04 1993-11-16 Ibex Technologies, Inc. Method for the enzymatic neutralization of heparin
US5389539A (en) * 1992-11-30 1995-02-14 Massachusetts Institute Of Technology Purification of heparinase I, II, and III from Flavobacterium heparinum
WO1995013091A1 (en) * 1993-11-12 1995-05-18 International Technology Management Associates, Ltd. Methods of repairing connective tissues
WO1995013830A1 (en) * 1993-11-17 1995-05-26 Massachusetts Institute Of Technology Method for inhibiting angiogenesis using heparinase

Also Published As

Publication number Publication date
AU3094995A (en) 1996-02-09
ATE344051T1 (en) 2006-11-15
JP4152433B2 (en) 2008-09-17
DE69535282T2 (en) 2007-05-24
EP0769961B1 (en) 2006-11-02
US5997863A (en) 1999-12-07
JPH10506609A (en) 1998-06-30
DE69535282D1 (en) 2006-12-14
AU707007B2 (en) 1999-07-01
EP0769961A1 (en) 1997-05-02
CA2194370C (en) 2001-02-27
ES2279514T3 (en) 2007-08-16
WO1996001648A1 (en) 1996-01-25

Similar Documents

Publication Publication Date Title
CA2194370A1 (en) Attenuation of wound healing processes
US9956273B2 (en) Compositions and methods for promoting neuronal outgrowth
WO2001039795A3 (en) Attenuation of fibroblast proliferation
AU1002497A (en) Method of inhibiting transformation, growth and metastasis of cells in which purine metabolic enzyme activity is elevated
IL157644A0 (en) Method for the purification of a protein preparation with erythropoietin activity
CA2320040A1 (en) Mesenchymal stem cells for prevention and treatment of immune responses in transplantation
CA2238360A1 (en) Enzymatic method and compositions for treating intravitreal hemorrhagic blood
CA2257077A1 (en) Treatment of diarrhea
MX9709472A (en) MUTANT 'alpha'-AMYLASE.
MX9700443A (en) Hard tissue stimulating agent.
WO1997035999A3 (en) Production of vanillin
EP0918461A4 (en) Methods of treating asthma with o-desulfated heparin
WO1998025597A3 (en) Method for treating and preventing heart failure and ventricular dilatation
AU1644295A (en) Cell culture substrates and methods of use
CA2146734A1 (en) Method for long term subculture of dermal papilla cells
NO974691L (en) Brewery Building
CA2211376A1 (en) Bio-erodible ophthalmic shield
AU2385195A (en) Chondroitinase ii and its use with chondroitinase i to achieve complete vitreal disinsertion
WO1999029279A3 (en) Long-term survival and regeneration of central nervous system neurons
Abraham et al. Direct enzyme transfer from lymphocytes corrects a lysosomal storage disease
EP0686397A3 (en) Use of chondroitin sulphate proteoglycans for protection of neurons
AU1076388A (en) High level expression in e. coli of soluble mature hil-beta and derivatives with altered biological activity
WO2000006713A3 (en) Methods for recombinant protein production in mammalian cells comprising co-expression with fetuin
WO2001035977A3 (en) Attenuation of tumor growth, metastasis and angiogenesis by use of chondroitin sulfate degrading enzymes
DK0858502T3 (en) Normal, neural epithelial precursor cells

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed